Estimands in Oncology: Are we censoring for the right reason?
Publié le
Estimands Framework: Ensuring alignment between the key scientific question of interest, analysis and interpretation during clinical trial design. The estimands…
Publié le
Estimands Framework: Ensuring alignment between the key scientific question of interest, analysis and interpretation during clinical trial design. The estimands…
Publié le
LEARN ON SAMPLE-SIZE RE-ESTIMATION, CONDITIONAL POWER AND THE PROMISING-ZONE METHOD. In this webinar, we will play the part of a sponsor consulting…
Publié le
Learn on history of bias and randomization in oncology clinical trials and how to think about what constitutes persuasive evidence…
Publié le
IDDI and XClinical webinar on the importance and the benefits Clinical Systems Integration WHAT YOU WILL LEARN:
Publié le
Improvements in the treatment of patients with cancer largely depend on clinical trials comparing a new intervention with a previous…
Publié le
Drug development in oncology in the era of precision medicine 08:30am – 09:30am (CET), 19th NOVEMBER, 2020 WATCH THE RECORDED…
Publié le
Recently, Erik Falvey, our Senior Director of Business Development, shared his insights during a Q&A session with Medicon Valley Alliance,…
Publié le
IDDI Complimentary Webinar on the need for integration of biomarker and IVD validation in clinical development Drug development in many…
Publié le
IDDI Complimentary Webinar on Immuno-Oncology Immuno-oncology is a buoyant field of research, with recently developed drugs showing unprecedented response rates…
Publié le
Adaptations to tumor response and progression criteria for immune therapies. Abstract Immuno-oncology is a buoyant field of research, with recently…